blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1745037

EP1745037 - Indolylmaleimide derivatives as inhibitors for the treatment of graft rejection or autoimmune diseases [Right-click to bookmark this link]
Former [2007/04]INDOLYLMALEIMIDE DERIVATIVES AS PKC INHIBITORS
[2012/37]
StatusNo opposition filed within time limit
Status updated on  08.11.2013
Database last updated on 05.10.2024
Most recent event   Tooltip17.07.2015Lapse of the patent in a contracting state
New state(s): HU, LU		published on 19.08.2015  [2015/34]
Applicant(s)For all designated states
Novartis AG
Lichtstrasse 35
4056 Basel / CH
[2010/44]
Former [2009/43]For:BE  BG  CH  CY  CZ  DE  DK  EE  ES  FI  FR  GB  GR  HU  IE  IS  IT  LI  LT  LU  MC 
Novartis AG
Lichtstrasse 35
4056 Basel / CH
For:AT 
Novartis Pharma GmbH
Brunner Strasse 59
1230 Wien / AT
Former [2007/04]For:BE  BG  CH  CY  CZ  DE  DK  EE  ES  FI  FR  GB  GR  HU  IE  IS  IT  LI  LT  LU  MC 
Novartis AG
Lichtstrasse 35
4056 Basel / CH
For:AT 
NOVARTIS-PHARMA GMBH
Brunner Strasse 59
1230 Vienna / AT
Inventor(s)01 / VAN EIS, Maurice
26, Rue de Wentzwiller
F-68220 Buschwiller / FR
02 / VON MATT, Peter
Fichtlirain 38
CH-4105 Biel-Benken BL / CH
03 / WAGNER, Jürgen
Nussbaumweg 24
CH-4103 Bottmingen / CH
04 / EVENOU, Jean-Pierre
Av. du Gal-de-Gaulle 10
F-68300 St. Louis / FR
05 / SCHULER, Walter
Kirchstr. 49
79639 Grenzach-Wyhlen / DE
 [2007/04]
Representative(s)Maucher, Wolfgang, et al
Patent- und Rechtsanwaltssozietät
Maucher, Börjes & Kollegen
Urachstrasse 23
79102 Freiburg im Breisgau / DE
[N/P]
Former [2013/01]Maucher, Wolfgang, et al
Patent- und Rechtsanwaltssozietät Maucher, Börjes & Kollegen Urachstrasse 23
79102 Freiburg im Breisgau / DE
Former [2009/09]Maucher, Wolfgang, et al
Patent- und Rechtsanwaltssozietät Maucher, Börjes & Kollegen Urachstrasse 23
79102 Freiburg i. Br. / DE
Former [2007/04]Crawley, Patrick Edward
Novartis AG Corporate Intellectual Property
4002 Basel / CH
Application number, filing date05701052.219.01.2005
[2007/04]
WO2005EP00502
Priority number, dateGB2004000108919.01.2004         Original published format: GB 0401089
GB2004000109019.01.2004         Original published format: GB 0401090
[2007/04]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2005068455
Date:28.07.2005
Language:EN
[2005/30]
Type: A1 Application with search report 
No.:EP1745037
Date:24.01.2007
Language:EN
The application published by WIPO in one of the EPO official languages on 28.07.2005 takes the place of the publication of the European patent application.
[2007/04]
Type: B1 Patent specification 
No.:EP1745037
Date:02.01.2013
Language:EN
[2013/01]
Search report(s)International search report - published on:EP28.07.2005
ClassificationIPC:C07D403/04, C07D401/14, // (C07D401/14, 213:00, 209:00), C07D207:00,(C07D403/04, 209:00), C07D207:00
[2013/01]
CPC:
C07D401/14 (EP,US); A61P1/02 (EP); A61P1/04 (EP);
A61P1/16 (EP); A61P11/00 (EP); A61P11/06 (EP);
A61P13/12 (EP); A61P15/08 (EP); A61P17/00 (EP);
A61P19/02 (EP); A61P21/00 (EP); A61P25/00 (EP);
A61P25/28 (EP); A61P29/00 (EP); A61P3/04 (EP);
A61P3/08 (EP); A61P31/00 (EP); A61P31/04 (EP);
A61P31/18 (EP); A61P35/00 (EP); A61P37/02 (EP);
A61P37/06 (EP); A61P43/00 (EP); A61P9/00 (EP);
A61P9/04 (EP); A61P9/08 (EP); A61P9/10 (EP);
A61P9/12 (EP); C07D403/04 (EP,US); C07D403/14 (EP,US) (-)
Former IPC [2007/04]C07D403/04, C07D401/14, // C07D401/14, C07D213/00, C07D209/00, C07D207/00, C07D403/04, C07D209/00, C07D207/00
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   MC,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2007/04]
TitleGerman:Zur Behandlung von Transplantatabstossung oder Autoimmunerkrankungen geeignete Indolylmaleimidderivate[2012/37]
English:Indolylmaleimide derivatives as inhibitors for the treatment of graft rejection or autoimmune diseases[2012/37]
French:Dérivés d'indolylmaléimide utiles pour le traitment de rejets de greffe ou de maladies auto-immunes[2012/37]
Former [2007/04]INDOLYLMALEIMIDDERIVATE ALS PKC-INHIBITOREN
Former [2007/04]INDOLYLMALEIMIDE DERIVATIVES AS PKC INHIBITORS
Former [2007/04]DERIVES INDOLYLMALEIMIDE UTILISES EN TANT QU'INHIBITEURS DE LA PKC
Entry into regional phase21.08.2006National basic fee paid 
21.08.2006Designation fee(s) paid 
21.08.2006Examination fee paid 
Examination procedure21.08.2006Examination requested  [2007/04]
09.10.2006Amendment by applicant (claims and/or description)
17.08.2007Despatch of a communication from the examining division (Time limit: M04)
19.12.2007Reply to a communication from the examining division
20.12.2011Despatch of a communication from the examining division (Time limit: M04)
07.04.2012Reply to a communication from the examining division
23.04.2012Despatch of a communication from the examining division (Time limit: M04)
26.07.2012Reply to a communication from the examining division
23.08.2012Communication of intention to grant the patent
20.11.2012Fee for grant paid
20.11.2012Fee for publishing/printing paid
Divisional application(s)EP10012694.5  / EP2270001
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  17.08.2007
Opposition(s)03.10.2013No opposition filed within time limit [2013/50]
Fees paidRenewal fee
31.01.2007Renewal fee patent year 03
14.01.2008Renewal fee patent year 04
14.01.2009Renewal fee patent year 05
13.01.2010Renewal fee patent year 06
14.01.2011Renewal fee patent year 07
11.01.2012Renewal fee patent year 08
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU19.01.2005
AT02.01.2013
BE02.01.2013
CY02.01.2013
CZ02.01.2013
DK02.01.2013
EE02.01.2013
FI02.01.2013
LT02.01.2013
NL02.01.2013
PL02.01.2013
RO02.01.2013
SE02.01.2013
SI02.01.2013
SK02.01.2013
TR02.01.2013
IE19.01.2013
LU19.01.2013
CH31.01.2013
LI31.01.2013
MC31.01.2013
BG02.04.2013
GR03.04.2013
IS02.05.2013
PT02.05.2013
[2015/34]
Former [2015/32]AT02.01.2013
BE02.01.2013
CY02.01.2013
CZ02.01.2013
DK02.01.2013
EE02.01.2013
FI02.01.2013
LT02.01.2013
NL02.01.2013
PL02.01.2013
RO02.01.2013
SE02.01.2013
SI02.01.2013
SK02.01.2013
TR02.01.2013
IE19.01.2013
CH31.01.2013
LI31.01.2013
MC31.01.2013
BG02.04.2013
GR03.04.2013
IS02.05.2013
PT02.05.2013
Former [2014/07]AT02.01.2013
BE02.01.2013
CY02.01.2013
CZ02.01.2013
DK02.01.2013
EE02.01.2013
FI02.01.2013
LT02.01.2013
NL02.01.2013
PL02.01.2013
RO02.01.2013
SE02.01.2013
SI02.01.2013
SK02.01.2013
IE19.01.2013
CH31.01.2013
LI31.01.2013
MC31.01.2013
BG02.04.2013
GR03.04.2013
IS02.05.2013
PT02.05.2013
Former [2013/52]AT02.01.2013
BE02.01.2013
CY02.01.2013
CZ02.01.2013
DK02.01.2013
EE02.01.2013
FI02.01.2013
LT02.01.2013
NL02.01.2013
PL02.01.2013
RO02.01.2013
SE02.01.2013
SI02.01.2013
SK02.01.2013
CH31.01.2013
LI31.01.2013
MC31.01.2013
BG02.04.2013
GR03.04.2013
IS02.05.2013
PT02.05.2013
Former [2013/49]AT02.01.2013
BE02.01.2013
CZ02.01.2013
DK02.01.2013
EE02.01.2013
FI02.01.2013
LT02.01.2013
NL02.01.2013
PL02.01.2013
RO02.01.2013
SE02.01.2013
SI02.01.2013
SK02.01.2013
CH31.01.2013
LI31.01.2013
MC31.01.2013
BG02.04.2013
GR03.04.2013
IS02.05.2013
PT02.05.2013
Former [2013/48]AT02.01.2013
BE02.01.2013
CZ02.01.2013
DK02.01.2013
EE02.01.2013
FI02.01.2013
LT02.01.2013
NL02.01.2013
PL02.01.2013
SE02.01.2013
SI02.01.2013
CH31.01.2013
LI31.01.2013
MC31.01.2013
BG02.04.2013
GR03.04.2013
IS02.05.2013
PT02.05.2013
Former [2013/40]AT02.01.2013
BE02.01.2013
CZ02.01.2013
FI02.01.2013
LT02.01.2013
NL02.01.2013
PL02.01.2013
SE02.01.2013
SI02.01.2013
MC31.01.2013
BG02.04.2013
GR03.04.2013
IS02.05.2013
PT02.05.2013
Former [2013/37]AT02.01.2013
BE02.01.2013
CZ02.01.2013
FI02.01.2013
LT02.01.2013
NL02.01.2013
PL02.01.2013
SE02.01.2013
SI02.01.2013
MC31.01.2013
BG02.04.2013
GR03.04.2013
IS02.05.2013
Former [2013/36]AT02.01.2013
BE02.01.2013
CZ02.01.2013
LT02.01.2013
PL02.01.2013
SE02.01.2013
SI02.01.2013
BG02.04.2013
IS02.05.2013
Former [2013/35]BE02.01.2013
CZ02.01.2013
LT02.01.2013
SE02.01.2013
SI02.01.2013
BG02.04.2013
IS02.05.2013
Former [2013/34]LT02.01.2013
SE02.01.2013
SI02.01.2013
BG02.04.2013
IS02.05.2013
Former [2013/33]LT02.01.2013
SI02.01.2013
Former [2013/26]SI02.01.2013
Cited inInternational search[DA]WO0238561  (NOVARTIS AG [CH], et al) [DA] 5-14,17 * page 1, title * * page 1, Formula I * * page 40, paragraph 2 ** page 41, last paragraph - page 42, first paragraph *
by applicantWO0238561
 WO03008259
    - MARTIN-BARON ET AL., JOURNAL OF BIOLOGICAL CHEMISTRY, (1993), vol. 268, no. 13, pages 9194 - 9197
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.